Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HER2 in Advanced NSCLC: an Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in Italy. The HEROS Study - GOIRC-01-2022

NCT07356544 is registered in ClinicalTrials.gov with Gruppo Oncologico Italiano di Ricerca Clinica as lead sponsor.

NCT NCT07356544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07356544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HER2 in Advanced NSCLC: an Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in Italy. The HEROS Study - GOIRC-01-2022
Lead sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Phase
Observational
Overall status
Recruiting
Start date
August 12, 2025
Completion date
January 31, 2027
Enrollment
50 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

her2, nsclc (advanced non-small cell lung cancer)